

Figure S1. The treatment with ovalbumin induces the phosphorylations of Akt and IKK α/β . (a–d) Murine GM-CSF and IL-4 treated BMPC was incubated with ovalbumin (50 $\mu\text{g}/\text{mL}$) for indicated periods. The recruitment of phosphorylated Akt (a) and IKK α/β (b) toward endosomes was assessed by immuno-fluorescent microscope. phosphorylated Akt or IKK α/β was stained with phosphorylated antibodies (red); Rab5 (green); Nuclei were counterstained with DAPI (blue). The co-localized spots of Rab5 with phosphorylated Akt (c) and IKK α/β (d) were counted and analyzed. Original magnification, $\times 600$. Data are presented as the mean \pm SEM, *** $p < 0.001$, one-way ANOVA with Newman-Keuls post test. One representative from 3 independent experiments is shown. Rab5: early endosome marker; OVA: ovalbumin.




Figure S2. The silencing of Akt, IKK α and IKK β decreases endotoxin-containing pathogen-induced phosphorylation of Akt and IKK α/β . Murine scramble, or Akt/IKK α /IKK β deficient BMPC was incubated with endotoxin-containing pathogen ovalbumin (50 $\mu\text{g}/\text{mL}$). The whole cellular protein was extracted and the phosphorylation of Akt and IKK α/β was assessed by western blot. Control siRNA with ovalbumin was used as endotoxin-containing pathogen control. Control siRNA without ovalbumin was used as scramble control. GAPDH was used as protein loading control. One representative from 3 independent experiments is shown. OVA: endotoxin-containing pathogen ovalbumin.




Figure S3. The treatments with wortmannin and Bay 11-7082 inhibit endotoxin-containing pathogen-derived cross-presentation in bone marrow precursor cells. Murine BMPC was pretreated with wortmannin (5 $\mu\text{mol/L}$) (**a**) or Bay11-7082 (5 $\mu\text{mol/L}$) (**b**) for 2 h prior to endotoxin-containing pathogen ovalbumin (50 $\mu\text{g/mL}$) incubation. The cross-presented OVA was observed with immuno-fluorescent microscope. Cross-presented OVA and Rab5 was stained with 25-D1.16 (red) or Rab5 antibody (green) respectively; nuclei were counter stained with DAPI (blue). The co-localized spots of 25-D1.16 with Rab5 were counted and analyzed (**c,d**). Data are presented as the mean \pm SEM, *** $p < 0.001$, one-way ANOVA with Newman-Keulspost test. One representative from 3 independent experiments is shown. Rab5: early endosome marker; OVA: endotoxin-containing pathogen ovalbumin.




Figure S4. The treatments with wortmannin and Bay11-7082 abolish endotoxin-containing pathogen-derived the endosomal relocation of phosphorylated Akt and IKK α/β . (a–d) Murine BMPC was pretreated with wortmannin (5 $\mu\text{mol/L}$) (a) or Bay11-7082 (5 $\mu\text{mol/L}$) (b) prior to endotoxin-containing pathogen ovalbumin (50 $\mu\text{g/mL}$) incubation and the relocation of phosphorylated Akt (a,c) and phosphorylated IKK α/β (b,d) was assessed by immuno-fluorescent microscope with related antibody staining. phosphorylated Akt (a), phosphorylated IKK α/β (b) were stained red; Rab5 was stained green; nuclei were counter stained with DAPI (blue). The co-localized spots of Rab5 with phosphorylated Akt (c), phosphorylated IKK α/β (d) were counted and analyzed. Data are presented as the mean \pm SEM, *** $p < 0.001$, one-way ANOVA with Newman-Keuls post test. One representative from 3 independent experiments is shown. Rab5: early endosome marker; OVA: endotoxin-containing pathogen ovalbumin.




Figure S5. The pretreatments with wortmannin and Bay 11-7082 decrease the interaction of Sec61 β with Rab5. Murine BMPC was pretreated with Bay11-7082/wortmannin (5 $\mu\text{mol/L}$) prior to endotoxin-containing pathogen ovalbumin (50 $\mu\text{g/mL}$) incubation. The interaction of Sec61 β with Rab5 was investigated by Co-IP with Rab5 antibody. Isotype IgG was used as negative control. DMSO with ovalbumin was used as endotoxin-containing pathogen control. DMSO without ovalbumin was used as scramble control. Rab5: early endosome marker; OVA: endotoxin-containing pathogen ovalbumin.




Figure S6. The pretreatments with wortmannin and Bay 11-7082 inhibit the relocation of Sec61 β . Murine scramble, or or Akt/IKK α /IKK β deficient BMPC was incubated with endotoxin-containing pathogen ovalbumin (50 $\mu\text{g/mL}$). The relocation of Sec61 β with Rab5 (a) was assessed by confocal microscope with related antibody staining. Sec61 β (a) was stained red; Rab5 was stained green; nuclei were counter stained with DAPI (blue). The co-localized spots of Rab5 with Sec61 β (b) were

counted and analyzed. Data are presented as the mean±SEM, *** $p < 0.001$, one-way ANOVA with Newman-Keuls post test. One representative from 3 independent experiments is shown. Rab5: early endosome marker; OVA: endotoxin-containing pathogen ovalbumin.




Figure S7. TRIF and MyD88 contribute to Akt+IKK α/β signalosome formation on Rab5+ endosomes and the relocation of Sec61 α toward endosomes. TRIF or MyD88 deficient BMPC was incubated with ovalbumin (50 $\mu\text{g}/\text{mL}$) and the formation of Akt+IKK α/β signalosome (**a,b**) or the relocation of Sec61 α toward endosomes (**c**) were assessed by immuno-fluorescent microscope. phosphorylated Akt (**a**), phosphorylated IKK α/β (**b**) and Sec61 α (**c**) were stained red; Rab5 was stained green; nuclei were counterstained with DAPI (blue). The co-localized spots of Rab5 with phosphorylated Akt (**d**), phosphorylated IKK α/β (**e**) and Sec61 α (**f**) were counted and analyzed. Original magnification, $\times 600$. Data are presented as the mean±SEM, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, one-way ANOVA with Newman-Keuls post test. One representative from 3 independent experiments is shown. Rab5: early endosome marker; OVA: ovalbumin; si: siRNA.




Figure S8. MyD88-IRAK4 augments antigenic cross-presentation in bone marrow precursor cells. (a–d) MyD88 or IRAK4 deficient BMPC was incubated with ovalbumin (50 $\mu\text{g}/\text{mL}$) and the effect of MyD88/IRAK4 deficiency on cross-presentation (a–d) was assessed by immuno-fluorescent microscope (a) and flow cytometric analyses (c,d), respectively. For immuno-fluorescent microscope, cross-presented OVA was stained with 25-D1.16 (red); Rab5 was stained green; nuclei were counter stained with DAPI (blue). The co-localized spots of Rab5 with 25D1.16 (b) was counted and analyzed. Original magnification, $\times 600$. Data are presented as the mean \pm SEM, ** $p < 0.01$, *** $p < 0.001$, one-way ANOVA with Newman-Keulspost test. One representative from 3 independent experiments is shown. Rab5: early endosome marker; OVA: ovalbumin; si: siRNA.